Ameriprise Financial Inc. lifted its position in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 282.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 227,609 shares of the company's stock after buying an additional 168,134 shares during the period. Ameriprise Financial Inc. owned approximately 0.28% of Editas Medicine worth $289,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also recently added to or reduced their stakes in the company. Ieq Capital LLC acquired a new stake in Editas Medicine in the 4th quarter valued at approximately $31,000. Dark Forest Capital Management LP increased its holdings in Editas Medicine by 66.9% in the 4th quarter. Dark Forest Capital Management LP now owns 32,787 shares of the company's stock valued at $42,000 after purchasing an additional 13,138 shares during the last quarter. Freestone Grove Partners LP acquired a new stake in Editas Medicine in the 4th quarter valued at approximately $46,000. Intech Investment Management LLC increased its holdings in Editas Medicine by 43.1% in the 4th quarter. Intech Investment Management LLC now owns 40,942 shares of the company's stock valued at $52,000 after purchasing an additional 12,336 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in Editas Medicine in the 4th quarter valued at approximately $90,000. Institutional investors and hedge funds own 71.90% of the company's stock.
Editas Medicine Stock Up 1.0%
Shares of EDIT stock traded up $0.02 during trading hours on Monday, reaching $1.93. 1,216,389 shares of the stock traded hands, compared to its average volume of 2,569,732. Editas Medicine, Inc. has a 1-year low of $0.91 and a 1-year high of $6.22. The business has a fifty day moving average price of $1.48 and a 200 day moving average price of $1.51. The firm has a market capitalization of $161.57 million, a PE ratio of -0.75 and a beta of 2.10.
Editas Medicine (NASDAQ:EDIT - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.08. The company had revenue of $4.66 million during the quarter, compared to the consensus estimate of $0.79 million. Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. During the same period in the previous year, the firm posted ($76.00) earnings per share. Research analysts expect that Editas Medicine, Inc. will post -2.71 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities analysts have commented on EDIT shares. Robert W. Baird dropped their price target on shares of Editas Medicine from $8.00 to $4.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. Wall Street Zen upgraded shares of Editas Medicine from a "sell" rating to a "hold" rating in a research note on Wednesday, May 14th. Cantor Fitzgerald upgraded shares of Editas Medicine from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 29th. Finally, HC Wainwright started coverage on shares of Editas Medicine in a research note on Monday, April 28th. They issued a "buy" rating and a $3.00 price target for the company. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, two have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Editas Medicine presently has an average rating of "Hold" and a consensus price target of $5.36.
View Our Latest Analysis on EDIT
Insider Buying and Selling at Editas Medicine
In other Editas Medicine news, CEO Gilmore Neil O'neill sold 15,192 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $1.72, for a total value of $26,130.24. Following the completion of the sale, the chief executive officer now owns 280,282 shares in the company, valued at approximately $482,085.04. This trade represents a 5.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 16,364 shares of company stock valued at $28,146 in the last ninety days. Company insiders own 2.10% of the company's stock.
About Editas Medicine
(
Free Report)
Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
Further Reading
Before you consider Editas Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Editas Medicine wasn't on the list.
While Editas Medicine currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
